Overview
Zevra Q3 2025 revenue of $26.1 mln missed analyst expectations
Net loss for Q3 2025 reduced significantly compared to Q3 2024
Revenue growth driven by MIPLYFFA performance in Niemann-Pick disease type C
Outlook
Company did not provide specific guidance for future quarters or years in press release
Result Drivers
MIPLYFFA PERFORMANCE - MIPLYFFA contributed $22.4 mln to Q3 revenue, driving overall revenue growth
OLPRUVA STRATEGY - Co scaling back OLPRUVA sales efforts due to limited market access, maintaining availability
PIPELINE PROGRESS - EMA reviewing arimoclomol for NPC; Celiprolol Phase 3 trial enrollment ongoing
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $26.06 mln | $26.63 mln (8 Analysts) |
Q3 Net Income | -$544,000 | ||
Q3 Income from Operations | $4.14 mln | ||
Q3 Operating Expenses | $20.37 mln | ||
Q3 Pretax Profit | -$977,000 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Zevra Therapeutics Inc is $25.00, about 60.8% above its November 4 closing price of $9.79
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago
Press Release: ID:nGNX7RNSm
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments